LATEST NEWS: 22 June 2026 In an important step toward improving outcomes for people with advanced lung cancer, TROG is set to launch a new international trial testing a novel radiation therapy approach for Australia’s deadliest cancer. The TROG 21.10/TOGA 20-005 PRIME-Lung (Primary Radiotherapy in Metastatic Lung) trial, which
TROG’s Facility Alliance Members (FAM) are the cornerstone of our collaborative outreach, supporting the implementation and delivery of TROG trials. In this series, we feature some of the many facilities that play a key role in advancing TROG trials, enabling us to recruit participants from diverse backgrounds. SITE NAME:
LATEST NEWS: 16 June 2026 TROG members highlighted cutting-edge radiation therapy research being led from Australia during wide-ranging presentations at the 17th International Stereotactic Radiosurgery Society (ISRS) Congress. The biennial congress, held in Sydney from 31 May – 3 June, brought together world-leading experts in stereotactic radiosurgery and radiation
LATEST NEWS: 10 June 2026 The global radiation therapy community is gearing up for World Radiotherapy Awareness Day (WRAD) on 7 September, to spread the word about the vital role of radiotherapy in treating cancer and the need for it to be made accessible to all people who can
LATEST NEWS: 4 June 2025 TROG’s latest Annual Research Report showcases a year of diverse, high-impact research, expanded international partnerships and deeper consumer engagement— all strengthening our work to improve cancer outcomes. The 2025 report showcases the many achievements of the year, which was marked by achieving several clinical
LATEST NEWS: 20 MAY A number of TROG trials and projects garnered international attention this month, as researchers presented findings at one of the world’s largest radiotherapy and oncology meetings, ESTRO26. Congratulations to the many TROG Members and research teams who contributed to the European Society of Radiotherapy and
LATEST NEWS: 18 MAY 2026 A new non-invasive form of radiation therapy achieves unprecedented 100% effectiveness in treating primary kidney cancers, findings from the world-leading TROG 15.03/ANZUP 16001 FASTRACK II trial reveal. The long-term findings from the phase II multi-centre trial suggest the rapidly emerging Stereotactic Ablative Body Radiation
LATEST NEWS: 14 May 2026 The need for greater focus on radiation therapy quality assurance (RTQA) in clinical trials has been highlighted by a recent review which reveals a very limited number of trials are implementing and reporting on this vital element of research. RTQA is an essential step
LATEST NEWS: 14 April 2026 TROG has made a commitment to involving consumer voices in all aspects of our work, from research strategy through to study delivery, as outlined in a new Consumer Engagement Charter. TROG President A/Prof Puma Sundaresan and TROG Board Independent Consumer Representative Mr Murray McLachlan
9 April 2026 TROG Cancer Research honours the life and legacy of Radiation Oncologist Professor Jim Denham OAM, a founding member and pioneering researcher whose contributions have been central to the organisation’s more than 35-year history. Jim passed away in March 2026 at the age of 75, leaving a
